npj Vaccines
A multidisciplinary journal that is dedicated to publishing the finest and high-quality research and development on human and veterinary vaccines.
Neoantigen Vaccine Nanoformulations based on Chemically Synthesized Minimal mRNA (CmRNA): Small Molecules, Big Impact
Our npj Vaccines article unveils a prospective breakthrough in personalized cancer immunotherapy, featuring Chemically Synthesized Minimal mRNA (CmRNA) in Lipid-Polymer Hybrid Nanoparticles (LPPs). This idea not only answers ongoing research needs but propels a paradigm shift in cancer treatment.
Bridging the gap: immunobridging large-scale efficacy data of a tetravalent dengue vaccine (TAK-003) from children and teenagers to adults
Behind the Paper : LeFevre, I., et al. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. NPJ Vaccines 8, 75 (2023).
Quadrivalent self-amplifying mRNA vaccines generate protective antibody and cell-mediated immunity to influenza
Self-amplifying mRNA is a promising platform for vaccine development, highlighted by our group's recent publication in npj Vaccines showing that a quadrivalent bicistronic sa-mRNA vaccine can generate protective immunity to both HA and NA from 4 influenza strains when formulated in a single vaccine.
Discovery of a natural IgA human monoclonal antibody against Mtb protein LpqH and its significance in TB prophylaxis
The discovery of a protective natural IgA human monoclonal antibody against LpqH, a major virulence factor in Mtb pathogenesis, from a naturally exposed asymptomatic donor, opens new avenues in TB vaccine development and prophylaxis.
Full-length MSP1 as a malaria vaccine: is there hope?
Successful immunisation studies in monkeys based on MSP1 involved the use of the full-length protein as a malaria vaccine. However, unsuccessful human trials only tested MSP1 subunits. We explore the potential of SumayaVac-1 to broadly stimulate immune mechanisms associated with protection.